Abcam, ab320866, Anti-Factor IX/PTC antibody [EPR28007-18] - BSA and Azide free (Detector)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Factor IX/PTC antibody. Carrier free. Suitable for sELISA and reacts with Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28007-18,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:sELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab320866 is a BSA and Azide free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Mouse/Rat Factor IX/PTC. The recommended pair for sandwich ELISA is:
Capture:
ab320865
, Mouse/Rat Factor IX/PTC Capture Antibody (unconjugated)
Detector: ab320866, Mouse/Rat Factor IX/PTC Detector Antibody (unconjugated)
The reference range value is 0.31-10 ng/mL.
The recommended antibody orientation is based on internal optimization for ELISA based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Sandwich ELISA
The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Factor IX also known as Christmas factor or PTC is an important clotting protein in the coagulation cascade. It is a 415 amino acid protein with a mass of approximately 55 kDa. Factor IX is mainly expressed in the liver and then released into the bloodstream where it plays a significant role in blood clotting processes. The recombinant version of this protein referred to as factor IX recombinant is used therapeutically especially in patients who require coagulation support due to factor deficiencies.
Biological function summary
The function of factor IX involves its role in the amplification phase of the coagulation cascade. It participates as part of the intrinsic tenase complex which forms on negatively charged phospholipids in the presence of calcium ions. This complex significantly enhances the conversion of factor X to its active form factor Xa an important step in the clotting process. The activity of factor IX can be assessed using assays such as the factor IX activity assay and ELISA allowing for precise measurement of its function and quantity.
Pathways
Factor IX is integral within the intrinsic pathway of blood coagulation. It interacts with proteins such as factor VIII and factor X. When activated factor IXa forms a complex with the cofactor factor VIIIa on membrane surfaces intensifying the transformation of factor X to factor Xa which then catalyzes the conversion of prothrombin to thrombin. This series of reactions leads to fibrin formation important for stable clot production. Factor IXa also relates to the pathways influencing cellular signaling and hemostasis.
Factor IX deficiencies cause hemophilia B a genetic disorder that leads to improper blood clotting. This disorder is mainly characterized by spontaneous bleeding or severe bleeding after injury. Patients with hemophilia B usually have mutations in the factor IX gene on the X chromosome affecting the protein's function. Successful treatment often involves replacement therapy using factor IX concentrates or the recombinant form. The interaction with proteases such as factor VIIa highlights its importance in therapeutic strategies for bleeding disorders.